论文部分内容阅读
目的观察分析利奈唑胺治疗重症监护病房感染患者的临床疗效和安全性。方法回顾性分析2007年6月-2009年2月在医院重症监护病房收治的31例患者,根据细菌培养结果或临床经验性给予利奈唑胺治疗,分析评价临床疗效。结果 31例患者痊愈患者9例(29.0%),显效患者16例(51.6%),进步患者4例(12.9%),无效患者2例(6.5%),总体临床有效率80.6%,在不同基础疾病、感染部位中治愈率差异无统计学意义;临床改善情况总体有效率79.6%,细菌清除率93.9%,总体临床有效率80.6%。结论利奈唑胺治疗重症监护病房革兰阳性菌感染安全性好,临床疗效卓越。
Objective To observe and analyze the clinical efficacy and safety of linezolid in patients with intensive care unit infection. Methods A retrospective analysis of 31 patients admitted to the intensive care unit from June 2007 to February 2009 was given linezolid in accordance with the results of bacterial culture or clinical experience, and the clinical efficacy was evaluated. Results Among the 31 patients, 9 (29.0%) were cured, 16 (51.6%) were effective, 4 (12.9%) were progressive, 2 (6.5%) were ineffective and the overall clinical response was 80.6% There was no significant difference in the cure rate of the disease and the infected site. The total effective rate of clinical improvement was 79.6%, the bacterial clearance rate was 93.9%, and the overall clinical effective rate was 80.6%. Conclusion linezolid treatment of intensive care unit Gram-positive bacteria infection, good clinical efficacy.